TITLE

What is the role of iFOBT in screening for colorectal cancer?

AUTHOR(S)
Ransohoff, David F.
PUB. DATE
October 2007
SOURCE
Gut;Oct2007, Vol. 56 Issue 10, p1343
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article discusses the Policy makers will need to consider if it has one, not only as an adjunct to Guaiac Fecal-Occult Blood Test (gFOBT) screening. As a primary screening test s creening for colorectal cancer using gFOBT has been shown in randomized controlled trials to reduce colorectal cancer mortality. A method that could determine which people with a positive gFOBT have false positive results.
ACCESSION #
27148456

 

Related Articles

  • Canadian Association of General Surgeons Evidence Based Reviews in Surgery. 10. McLeod, Robin S.; Stern, Hartley // Canadian Journal of Surgery;Jun2004, Vol. 47 Issue 3, p209 

    The article presents a randomized controlled trial of Laparoscopy-assisted Colectomy (LAC) versus Open Colectomy (OC) for treatment of non-metastatic colon cancer. Two hundred and nineteen of 442 eligible patients with adenocarcinoma of the colon were included. Patients were excluded if the...

  • Screening for Colorectal Cancer with Flexible Sigmoidoscopy: Is a 5-Yr Interval Appropriate? A Comparison of the Detection of Neoplasia 3 Yr versus 5 Yr After a Normal Examination. Burke, Carol A.; Elder, Kareem; Lopez, Rocio // American Journal of Gastroenterology;Jun2006, Vol. 101 Issue 6, p1329 

    CONTEXT: The recommended interval for colorectal cancer screening with flexible sigmoidoscopy (FS) was recently lengthened from 3 to 5 yr. Direct evidence supporting the longer interval is lacking. The appropriateness of the longer interval has been questioned. OBJECTIVE: To compare the...

  • Is there another way to take account of noncompliance in randomized controlled trials? Hewitt, Catherine E.; Torgerson, David J.; Miles, Jeremy N. V. // CMAJ: Canadian Medical Association Journal;8/15/2006, Vol. 175 Issue 4, p347 

    This article focuses on alternative ways of taking account of noncompliance in the design and conduct of randomized controlled trials (RCT). It has been recommended that the primary analysis of an RCT should utilize intention to treat (ITT). An alternative to the ITT approach is the complier...

  • Amgen and Abgenix cancer treatment shows promise in colorectal cancer.  // PharmaWatch: Cancer;December2004, Vol. 3 Issue 12, p8 

    Cites the results of the phase II study evaluating the efficacy of Amgen Inc.'s and Abgenix Inc.'s co-developed cancer treatment, panitumumab, in patients with metastatic colorectal cancer. Observation of progression-free survival in patients administered with panitumumab; Tolerance of study...

  • Human Genome Sciences' genomics- derived anticancer drug enters phase II trials.  // PharmaWatch: Cancer;December2004, Vol. 3 Issue 12, p11 

    Reports that Human Genome Sciences Inc. has begun two phase II clinical trials to evaluate the efficacy of agonistic human monoclonal antibody to TRAIL receptor-1 (HGS-ETR1) in advanced non-Hodgkin's lymphoma and colorectal cancer patients. Clinical trial objectives; Comments of Craig A. Rosen,...

  • Five fractions of preoperative radiotherapy for selected cases of rectal cancer. Pistevou-Gompaki, K. // Techniques in Coloproctology;Nov2004 Supplement 1, Vol. 8, ps36 

    In locally advanced colorectal cancer, combined modality treatment is a standard adjuvant therapy in USA and Europe. The basic issue of the timing of radiotherapy and chemotherapy and preoperative radio-chemotherapy versus postoperative radio-chemotherapy is being addressed in prospective...

  • NeoPharm colorectal cancer drug misses target.  // PharmaWatch: Cancer;May2007, Vol. 6 Issue 5, p16 

    The article reports on the announcement of biopharmaceutical company NeoPharm Inc. on the failure of its phase II trial in second-line metastatic colorectal cancer patients with its product LESN38 to produce the desired results. While the interim analysis of data following the completion of...

  • Amgen's Phase III colorectal cancer fails secondary endpoint.  // PharmaWatch: Biotechnology;Dec2009, Vol. 8 Issue 12, p9 

    The article reports that Amgen Inc.'s Phase III Prime 203 trial for Vectibix has failed to meet a secondary endpoint of overall survival in the U.S. It states that the trial evaluated Vectibix in combination with Folfox to treat metastatic colorectal cancer (mCRC). It cites the result of the...

  • Pegylated Metabolite of Camptosar Moves Forward.  // Bioworld Week;6/29/2009, Vol. 17 Issue 26, p3 

    The article reports on the status of the Phase II trial of Enzon Pharmaceuticals Inc.'s PEG-SN38, an active metabolite of Camptosar used in treating metastatuc colorectal cancer, in Bridgewater, New Jersey. The company initiated the study of PEG-SN38 earlier than the planned date, wherein it...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sign out of this library

Other Topics